MellingMedical will offer Kerecis‘ fish-skin-based wound treatment product to the Department of Veterans Affairs through the Federal Supply Schedule contract vehicle.
The Kerecis Omega3 Wound product works to utilize patented fish-skin-based material for skin grafting and tissue repair operations among military veteran patients, Kerecis said Friday.
The company noted that minimally processed fish skin retains natural elements such as Omega3 polyunsaturated fatty acids to support the treatment of chronic and persistent wounds such as diabetic, venous, foot and pressure ulcers.
Fish skin does not pose a risk of transmitting diseases to humans and addresses potential disadvantages of traditional grafting materials such as cadaver skin and skin from the patient’s healthy body parts, Kerecis added.
Kerecis CEO Fertram Sigurjonsson said the company will work with the Defense Department to research other applications for the material.
The company has also partnered with the Office of Naval Research to study the use of Kerecis’ fish skin graft for battlefield trauma wounds.
Kerecis develops regenerative technologies based on fish skin and Omega3 polyunsaturated fatty acids.
Kerecis Omega3 Wound is approved by the U.S. Food and Drug Administration and European regulatory authorities for wound treatment.